Product Description
Telratolimod is a toll-like receptor type 7 and 8 (TLR7/8) agonist with potential immunostimulating and antitumor activities. Upon intratumoral administration, telratolimod binds to and activates TLR7 and 8, thereby stimulating antigen-presenting cells (APCs), including dendritic cells (DCs). Activation of DCs results in the production of proinflammatory cytokines, and the activation of cytotoxic T-lymphocyte (CTL) and B-lymphocyte immune responses. This may cause tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the immune system. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Telratolimod)
Mechanisms of Action: TLR7 Agonist,TLR8 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified|HIV Infections|Acquired Immunodeficiency Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HVTN 309 | P1 |
Not yet recruiting |
HIV Infections|Acquired Immunodeficiency Syndrome |
2025-12-30 |
|
| HVTN 807 | P1 |
Recruiting |
HIV Infections |
2025-12-20 |
|
| HVTN 307 | P1 |
Active, not recruiting |
HIV Infections |
2025-08-30 |
|
| D6410C00001 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2018-10-26 |
41% |